Role of the TWEAK-Fn14-cIAP1-NF-κB signaling axis in the regulation of myogenesis and muscle homeostasis

Frontiers in Immunology

Volumn 5, Issue FEB, 2014, Pages

  Enwere, Emeka K ^a   LaCasse, Eric C ^b   Adam, Nadine J ^b,c   Korneluk, Robert G ^b,c  

^a UNIVERSITY OF ALBERTA   (Canada)

^b CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

Author keywords

CIAP1; Fn14; Muscle regeneration; Myoblast fusion; Myogenesis; NF B signaling; TWEAK

Indexed keywords

FIBROBLAST GROWTH FACTOR 14; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN 1; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; DIABETES MELLITUS; DIMERIZATION; DOWN REGULATION; GENE EXPRESSION; GLUCOSE METABOLISM; HOMEOSTASIS; IMMUNE RESPONSE; INFLAMMATION; INNATE IMMUNITY; MUSCLE ATROPHY; MUSCLE DEVELOPMENT; MUSCLE REGENERATION; NONHUMAN; OLIGOMERIZATION; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; UBIQUITINATION; UPREGULATION;

EID: 84897584526     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00034     Document Type: Review

References (144)

1. Yin H, Price F, Rudnicki MA. Satellite cells and the muscle stem cell niche. Physiol Rev (2013) 93(1):23-67. doi:10.1152/physrev.00043.2011.
2. Birbrair A, Zhang T, Wang ZM, Messi ML, Enikolopov GN, Mintz A, et al. Role of pericytes in skeletal muscle regeneration and fat accumulation. Stem Cells Dev (2013) 22(16):2298-314. doi:10.1089/scd.2012.0647.
3. Sato S, Ogura Y, Kumar A. TWEAK/Fn14 signaling axis mediates skeletal muscle atrophy and metabolic dysfunction. Front Immunol (2014) 5:18. doi:10.3389/fimmu.2014.00018.
4. Feng SL, Guo Y, Factor VM, Thorgeirsson SS, Bell DW, Testa JR, et al. The Fn14 immediate-early response gene is induced during liver regeneration and highly expressed in both human and murine hepatocellular carcinomas. Am J Pathol (2000) 156(4):1253-61. doi:10.1016/S0002-9440(10)64996-6.
5. Wiley SR, Cassiano L, Lofton T, Davis-Smith T, Winkles JA, Lindner V, et al. A novel TNF receptor family member binds TWEAK and is implicated in angiogenesis. Immunity (2001) 15(5):837-46. doi:10.1016/S1074-7613(01)00232-1.
6. Meighan-Mantha RL, Hsu DK, Guo Y, Brown SA, Feng SL, Peifley KA, et al. The mitogen-inducible Fn14 gene encodes a type I transmembrane protein that modulates fibroblast adhesion and migration. J Biol Chem (1999) 274(46):33166-76. doi:10.1074/jbc.274.46.33166.
7. Brown SA, Richards CM, Hanscom HN, Feng SL, Winkles JA. The Fn14 cytoplasmic tail binds tumour-necrosis-factor-receptor-associated factors 1, 2, 3 and 5 and mediates nuclear factor-kappaB activation. Biochem J (2003) 371(Pt 2):395-403. doi:10.1042/BJ20021730.
8. Wicovsky A, Salzmann S, Roos C, Ehrenschwender M, Rosenthal T, Siegmund D, et al. TNF-like weak inducer of apoptosis inhibits proinflammatory TNF receptor-1 signaling. Cell Death Differ (2009) 16(11):1445-59. doi:10.1038/cdd.2009.80.
9. Burkly LC, Michaelson JS, Zheng TS. TWEAK/Fn14 pathway: an immunological switch for shaping tissue responses. Immunol Rev (2011) 244(1):99-114. doi:10.1111/j.1600-065X.2011.01054.x.
10. Bossen C, Ingold K, Tardivel A, Bodmer JL, Gaide O, Hertig S, et al. Interactions of tumor necrosis factor (TNF) and TNF receptor family members in the mouse and human. J Biol Chem (2006) 281(20):13964-71. doi:10.1074/jbc.M601553200.
11. Bover LC, Cardo-Vila M, Kuniyasu A, Sun J, Rangel R, Takeya M, et al. A previously unrecognized protein-protein interaction between TWEAK and CD163: potential biological implications. J Immunol (2007) 178(12):8183-94.
12. Polek TC, Talpaz M, Darnay BG, Spivak-Kroizman T. TWEAK mediates signal transduction and differentiation of RAW264.7 cells in the absence of Fn14/TweakR. Evidence for a second TWEAK receptor. J Biol Chem (2003) 278(34):32317-23. doi:10.1074/jbc.M302518200.
13. Zhou H, Marks JW, Hittelman WN, Yagita H, Cheung LH, Rosenblum MG, et al. Development and characterization of a potent immunoconjugate targeting the Fn14 receptor on solid tumor cells. Mol Cancer Ther (2011) 10(7):1276-88. doi:10.1158/1535-7163.MCT-11-0161.
14. Brown SA, Cheng E, Williams MS, Winkles JA. TWEAK-independent Fn14 self-association and NF-kappaB activation is mediated by the C-terminal region of the Fn14 cytoplasmic domain. PLoS One (2013) 8(6):e65248. doi:10.1371/journal.pone.0065248.
15. Girgenrath M, Weng S, Kostek CA, Browning B, Wang M, Brown SA, et al. TWEAK, via its receptor Fn14, is a novel regulator of mesenchymal progenitor cells and skeletal muscle regeneration. EMBO J (2006) 25(24):5826-39. doi:10.1038/sj.emboj.7601441.
16. Dogra C, Hall SL, Wedhas N, Linkhart TA, Kumar A. Fibroblast growth factor inducible 14 (Fn14) is required for the expression of myogenic regulatory factors and differentiation of myoblasts into myotubes. Evidence for TWEAK-independent functions of Fn14 during myogenesis. J Biol Chem (2007) 282(20):15000-10. doi:10.1074/jbc.M608668200.
17. Enwere EK, Holbrook J, Lejmi-Mrad R, Vineham J, Timusk K, Sivaraj B, et al. TWEAK and cIAP1 regulate myoblast fusion through the noncanonical NF-kappaB signaling pathway. Sci Signal (2012) 5(246):ra75. doi:10.1126/scisignal.2003086.
18. Vince JE, Chau D, Callus B, Wong WW, Hawkins CJ, Schneider P, et al. TWEAK-FN14 signaling induces lysosomal degradation of a cIAP1-TRAF2 complex to sensitize tumor cells to TNF alpha. J Cell Biol (2008) 182(1):171-84. doi:10.1083/jcb.200801010.
19. Varfolomeev E, Goncharov T, Maecker H, Zobel K, Komuves LG, Deshayes K, et al. Cellular inhibitors of apoptosis are global regulators of NF-kappaB and MAPK activation by members of the TNF family of receptors. Sci Signal (2012) 5(216):ra22. doi:10.1126/scisignal.2001878.
20. Oh H, Ghosh S. NF-kappaB: roles and regulation in different CD4(+) T-cell subsets. Immunol Rev (2013) 252(1):41-51. doi:10.1111/imr.12033.
21. Rothe M, Pan MG, Henzel WJ, Ayres TM, Goeddel DV. The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins. Cell (1995) 83(7):1243-52. doi:10.1016/0092-8674(95)90149-3.
22. Shu HB, Takeuchi M, Goeddel DV. The tumor necrosis factor receptor 2 signal transducers TRAF2 and c-IAP1 are components of the tumor necrosis factor receptor 1 signaling complex. Proc Natl Acad Sci U S A (1996) 93(24):13973-8. doi:10.1073/pnas.93.24.13973.
23. Uren AG, Pakusch M, Hawkins CJ, Puls KL, Vaux DL. Cloning and expression of apoptosis inhibitory protein homologs that function to inhibit apoptosis and/or bind tumor necrosis factor receptor-associated factors. Proc Natl Acad Sci U S A (1996) 93(10):4974-8. doi:10.1073/pnas.93.10.4974.
24. Chu ZL, Mckinsey TA, Liu L, Gentry JJ, Malim MH, Ballard DW. Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-kappaB control. Proc Natl Acad Sci U S A (1997) 94(19):10057-62. doi:10.1073/pnas.94.19.10057.
25. Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS Jr. NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science (1998) 281(5383):1680-3. doi:10.1126/science.281.5383.1680.
26. Varfolomeev E, Blankenship JW, Wayson SM, Fedorova AV, Kayagaki N, Garg P, et al. IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell (2007) 131(4):669-81. doi:10.1016/j.cell.2007.10.030.
27. Vince JE, Wong WW, Khan N, Feltham R, Chau D, Ahmed AU, et al. IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. Cell (2007) 131(4):682-93. doi:10.1016/j.cell.2007.10.037.
28. Mahoney DJ, Cheung HH, Mrad RL, Plenchette S, Simard C, Enwere E, et al. Both cIAP1 and cIAP2 regulate TNFalpha-mediated NF-kappaB activation. Proc Natl Acad Sci U S A (2008) 105(33):11778-83. doi:10.1073/pnas.0711122105.
29. Varfolomeev E, Goncharov T, Fedorova AV, Dynek JN, Zobel K, Deshayes K, et al. c-IAP1 and c-IAP2 are critical mediators of tumor necrosis factor alpha (TNFalpha)-induced NF-kappaB activation. J Biol Chem (2008) 283(36):24295-9. doi:10.1074/jbc.C800128200.
30. Crook NE, Clem RJ, Miller LK. An apoptosis-inhibiting baculovirus gene with a zinc finger-like motif. J Virol (1993) 67(4):2168-74.
31. Roy N, Mahadevan MS, Mclean M, Shutler G, Yaraghi Z, Farahani R, et al. The gene for neuronal apoptosis inhibitory protein is partially deleted in individuals with spinal muscular atrophy. Cell (1995) 80(1):167-78. doi:10.1016/0092-8674(95)90461-1.
32. Liston P, Roy N, Tamai K, Lefebvre C, Baird S, Cherton-Horvat G, et al. Suppression of apoptosis in mammalian cells by NAIP and a related family of IAP genes. Nature (1996) 379(6563):349-53. doi:10.1038/379349a0.
33. Zarnegar BJ, Wang Y, Mahoney DJ, Dempsey PW, Cheung HH, He J, et al. Noncanonical NF-kappaB activation requires coordinated assembly of a regulatory complex of the adaptors cIAP1, cIAP2, TRAF2 and TRAF3 and the kinase NIK. Nat Immunol (2008) 9(12):1371-8. doi:10.1038/ni.1676.
34. Zhou AY, Shen RR, Kim E, Lock YJ, Xu M, Chen ZJ, et al. IKK epsilon-mediated tumorigenesis requires K63-linked polyubiquitination by a cIAP1/cIAP2/TRAF2 E3 ubiquitin ligase complex. Cell Rep (2013) 3(3):724-33. doi:10.1016/j.celrep.2013.01.031.
35. Hinz M, Stilmann M, Arslan SC, Khanna KK, Dittmar G, Scheidereit C. A cytoplasmic ATM-TRAF6-cIAP1 module links nuclear DNA damage signaling to ubiquitin-mediated NF-kappaB activation. Mol Cell (2010) 40(1):63-74. doi:10.1016/j.molcel.2010.09.008.
36. Zheng C, Kabaleeswaran V, Wang Y, Cheng G, Wu H. Crystal structures of the TRAF2: cIAP2 and the TRAF1: TRAF2: cIAP2 complexes: affinity, specificity, and regulation. Mol Cell (2010) 38(1):101-13. doi:10.1016/j.molcel.2010.03.009.
37. Yang Y, Fang S, Jensen JP, Weissman AM, Ashwell JD. Ubiquitin protein ligase activity of IAPs and their degradation in proteasomes in response to apoptotic stimuli. Science (2000) 288(5467):874-7. doi:10.1126/science.288.5467.874.
38. Gyrd-Hansen M, Darding M, Miasari M, Santoro MM, Zender L, Xue W, et al. IAPs contain an evolutionarily conserved ubiquitin-binding domain that regulates NF-kappaB as well as cell survival and oncogenesis. Nat Cell Biol (2008) 10(11):1309-17. doi:10.1038/ncb1789.
39. Conze DB, Albert L, Ferrick DA, Goeddel DV, Yeh WC, Mak T, et al. Posttranscriptional downregulation of c-IAP2 by the ubiquitin protein ligase c-IAP1 in vivo. Mol Cell Biol (2005) 25(8):3348-56. doi:10.1128/MCB.25.8.3348-3356.2005.
40. Schoemaker MH, Ros JE, Homan M, Trautwein C, Liston P, Poelstra K, et al. Cytokine regulation of pro-and anti-apoptotic genes in rat hepatocytes: NF-kappaB-regulated inhibitor of apoptosis protein 2 (cIAP2) prevents apoptosis. J Hepatol (2002) 36(6):742-50. doi:10.1016/S0168-8278(02)00063-6.
41. Mitsiades CS, Mitsiades N, Poulaki V, Schlossman R, Akiyama M, Chauhan D, et al. Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene (2002) 21(37):5673-83. doi:10.1038/sj.onc.1205664.
42. Zhao X, Laver T, Hong SW, Twitty GB Jr, Devos A, Devos M, et al. An NF-kappaB p65-cIAP2 link is necessary for mediating resistance to TNF-alpha induced cell death in gliomas. J Neurooncol (2011) 102(3):367-81. doi:10.1007/s11060-010-0346-y.
43. Dynek JN, Goncharov T, Dueber EC, Fedorova AV, Izrael-Tomasevic A, Phu L, et al. c-IAP1 and UbcH5 promote K11-linked polyubiquitination of RIP1 in TNF signalling. EMBO J (2010) 29(24):4198-209. doi:10.1038/emboj.2010.300.
44. Tenev T, Bianchi K, Darding M, Broemer M, Langlais C, Wallberg F, et al. The ripoptosome, a signaling platform that assembles in response to genotoxic stress and loss of IAPs. Mol Cell (2011) 43(3):432-48. doi:10.1016/j.molcel.2011.06.006.
45. Feoktistova M, Geserick P, Kellert B, Dimitrova DP, Langlais C, Hupe M, et al. cIAPs block ripoptosome formation, a RIP1/caspase-8 containing intracellular cell death complex differentially regulated by cFLIP isoforms. Mol Cell (2011) 43(3):449-63. doi:10.1016/j.molcel.2011.06.011.
46. Ikner A, Ashkenazi A. TWEAK induces apoptosis through a death-signaling complex comprising receptor-interacting protein 1 (RIP1), Fas-associated death domain (FADD), and caspase-8. J Biol Chem (2011) 286(24):21546-54. doi:10.1074/jbc.M110.203745.
47. Roos C, Wicovsky A, Muller N, Salzmann S, Rosenthal T, Kalthoff H, et al. Soluble and transmembrane TNF-like weak inducer of apoptosis differentially activate the classical and noncanonical NF-kappa B pathway. J Immunol (2010) 185(3):1593-605. doi:10.4049/jimmunol.0903555.
48. Salzmann S, Seher A, Trebing J, Weisenberger D, Rosenthal A, Siegmund D, et al. Fibroblast growth factor inducible (Fn14)-specific antibodies concomitantly display signaling pathway-specific agonistic and antagonistic activity. J Biol Chem (2013) 288(19):13455-66. doi:10.1074/jbc.M112.435917.
49. Trebing J, Lang I, Chopra M, Salzmann S, Moshir M, Silence K, et al. A novel llama antibody targeting Fn14 exhibits anti-metastatic activity in vivo. MAbs (2014) 6(1):297-308. doi:10.4161/mabs.26709.
50. Mittal A, Bhatnagar S, Kumar A, Lach-Trifilieff E, Wauters S, Li H, et al. The TWEAK-Fn14 system is a critical regulator of denervation-induced skeletal muscle atrophy in mice. J Cell Biol (2010) 188(6):833-49. doi:10.1083/jcb.200909117.
51. Mourkioti F, Rosenthal N. NF-kappaB signaling in skeletal muscle: prospects for intervention in muscle diseases. J Mol Med (2008) 86(7):747-59. doi:10.1007/s00109-008-0308-4.
52. Bakkar N, Guttridge DC. NF-kappaB signaling: a tale of two pathways in skeletal myogenesis. Physiol Rev (2010) 90(2):495-511. doi:10.1152/physrev.00040.2009.
53. Peterson JM, Bakkar N, Guttridge DC. NF-kappaB signaling in skeletal muscle health and disease. Curr Top Dev Biol (2011) 96:85-119. doi:10.1016/B978-0-12-385940-2.00004-8.
54. Tidball JG, Villalta SA. Regulatory interactions between muscle and the immune system during muscle regeneration. Am J Physiol Regul Integr Comp Physiol (2010) 298(5):R1173-87. doi:10.1152/ajpregu.00735.2009.
55. Merritt EK, Thalacker-Mercer A, Cross JM, Windham ST, Thomas SJ, Bamman MM. Increased expression of atrogenes and TWEAK family members after severe burn injury in nonburned human skeletal muscle. J Burn Care Res (2013) 34(5):e297-304. doi:10.1097/BCR.0b013e31827a2a9c.
56. Tidball JG. Inflammatory processes in muscle injury and repair. Am J Physiol Regul Integr Comp Physiol (2005) 288(2):R345-53. doi:10.1152/ajpregu.00454.2004.
57. Vallabhapurapu S, Matsuzawa A, Zhang W, Tseng PH, Keats JJ, Wang H, et al. Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-kappaB signaling. Nat Immunol (2008) 9(12):1364-70. doi:10.1038/ni.1678.
58. Liao G, Zhang M, Harhaj EW, Sun SC. Regulation of the NF-kappaB-inducing kinase by tumor necrosis factor receptor-associated factor 3-induced degradation. J Biol Chem (2004) 279(25):26243-50. doi:10.1074/jbc.M403286200.
59. Feltham R, Moulin M, Vince JE, Mace PD, Wong WW, Anderton H, et al. Tumor necrosis factor (TNF) signaling, but not TWEAK (TNF-like weak inducer of apoptosis)-triggered cIAP1 (cellular inhibitor of apoptosis protein 1) degradation, requires cIAP1 RING dimerization and E2 binding. J Biol Chem (2010) 285(23):17525-36. doi:10.1074/jbc.M109.087635.
60. Darding M, Feltham R, Tenev T, Bianchi K, Benetatos C, Silke J, et al. Molecular determinants of smac mimetic induced degradation of cIAP1 and cIAP2. Cell Death Differ (2011) 18(8):1376-86. doi:10.1038/cdd.2011.10.
61. Salzmann S, Lang I, Rosenthal A, Schafer V, Weisenberger D, Carmona Arana JA, et al. TWEAK inhibits TRAF2-mediated CD40 signaling by destabilization of CD40 signaling complexes. J Immunol (2013) 191(5):2308-18. doi:10.4049/jimmunol.1202899.
62. Tisdale MJ. Mechanisms of cancer cachexia. Physiol Rev (2009) 89(2):381-410. doi:10.1152/physrev.00016.2008.
63. Jackman RW, Cornwell EW, Wu CL, Kandarian SC. Nuclear factor-kappaB signalling and transcriptional regulation in skeletal muscle atrophy. Exp Physiol (2013) 98(1):19-24. doi:10.1113/expphysiol.2011.063321.
64. Canicio J, Ruiz-Lozano P, Carrasco M, Palacin M, Chien K, Zorzano A, et al. Nuclear factor kappa B-inducing kinase and Ikappa B kinase-alpha signal skeletal muscle cell differentiation. J Biol Chem (2001) 276(23):20228-33. doi:10.1074/jbc.M100718200.
65. Bakkar N, Wang J, Ladner KJ, Wang H, Dahlman JM, Carathers M, et al. IKK/NF-kappaB regulates skeletal myogenesis via a signaling switch to inhibit differentiation and promote mitochondrial biogenesis. J Cell Biol (2008) 180(4):787-802. doi:10.1083/jcb.200707179.
66. Bakkar N, Ladner K, Canan BD, Liyanarachchi S, Bal NC, Pant M, et al. IKK alpha and alternative NF-kappaB regulate PGC-1beta to promote oxidative muscle metabolism. J Cell Biol (2012) 196(4):497-511. doi:10.1083/jcb.201108118.
67. He WA, Berardi E, Cardillo VM, Acharyya S, Aulino P, Thomas-Ahner J, et al. NF-kappaB-mediated Pax7 dysregulation in the muscle microenvironment promotes cancer cachexia. J Clin Invest (2013) 123(11):4821-35. doi:10.1172/JCI68523.
68. Shembade N, Ma A, Harhaj EW. Inhibition of NF-kappaB signaling by A20 through disruption of ubiquitin enzyme complexes. Science (2010) 327(5969):1135-9. doi:10.1126/science.1182364.
69. Yamaguchi N, Oyama M, Kozuka-Hata H, Inoue J. Involvement of A20 in the molecular switch that activates the non-canonical NF-small ka, Cyrillic B pathway. Sci Rep (2013) 3:2568. doi:10.1038/srep02568.
70. Charan RA, Hanson R, Clemens PR. Deubiquitinating enzyme A20 negatively regulates NF-kappaB signaling in skeletal muscle in mdx mice. FASEB J (2012) 26(2):587-95. doi:10.1096/fj.11-189829.
71. Mittal A, Bhatnagar S, Kumar A, Paul PK, Kuang S. Genetic ablation of TWEAK augments regeneration and post-injury growth of skeletal muscle in mice. Am J Pathol (2010) 177(4):1732-42. doi:10.2353/ajpath.2010.100335.
72. Dogra C, Changotra H, Mohan S, Kumar A. Tumor necrosis factor-like weak inducer of apoptosis inhibits skeletal myogenesis through sustained activation of nuclear factor-kappaB and degradation of MyoD protein. J Biol Chem (2006) 281(15):10327-36. doi:10.1074/jbc.M511131200.
73. Ogura Y, Mishra V, Hindi SM, Kuang S, Kumar A. Proinflammatory cytokine tumor necrosis factor (TNF)-like weak inducer of apoptosis (TWEAK) suppresses satellite cell self-renewal through inversely modulating notch and NF-κB signaling pathways. J Biol Chem (2013) 288(49):35159-69. doi:10.1074/jbc.M113.517300.
74. Kuramitsu K, Sverdlov DY, Liu SB, Csizmadia E, Burkly L, Schuppan D, et al. Failure of fibrotic liver regeneration in mice is linked to a severe fibrogenic response driven by hepatic progenitor cell activation. Am J Pathol (2013) 183(1):182-94. doi:10.1016/j.ajpath.2013.03.018.
75. Ucero AC, Benito-Martin A, Fuentes-Calvo I, Santamaria B, Blanco J, Lopez-Novoa JM, et al. TNF-related weak inducer of apoptosis (TWEAK) promotes kidney fibrosis and Ras-dependent proliferation of cultured renal fibroblast. Biochim Biophys Acta (2013) 1832(10):1744-55. doi:10.1016/j.bbadis.2013.05.032.
76. Haile WB, Echeverry R, Wu F, Guzman J, An J, Wu J, et al. Tumor necrosis factor-like weak inducer of apoptosis and fibroblast growth factor-inducible 14 mediate cerebral ischemia-induced poly(ADP-ribose) polymerase-1 activation and neuronal death. Neuroscience (2010) 171(4):1256-64. doi:10.1016/j.neuroscience.2010.10.029.
77. Morosetti R, Gliubizzi C, Sancricca C, Broccolini A, Gidaro T, Lucchini M, et al. TWEAK in inclusion-body myositis muscle: possible pathogenic role of a cytokine inhibiting myogenesis. Am J Pathol (2012) 180(4):1603-13. doi:10.1016/j.ajpath.2011.12.027.
78. Jakubowski A, Ambrose C, Parr M, Lincecum JM, Wang MZ, Zheng TS, et al. TWEAK induces liver progenitor cell proliferation. J Clin Invest (2005) 115(9):2330-40. doi:10.1172/JCI23486.
79. Novoyatleva T, Diehl F, van Amerongen MJ, Patra C, Ferrazzi F, Bellazzi R, et al. TWEAK is a positive regulator of cardiomyocyte proliferation. Cardiovasc Res (2010) 85(4):681-90. doi:10.1093/cvr/cvp360.
80. Tirnitz-Parker JE, Viebahn CS, Jakubowski A, Klopcic BR, Olynyk JK, Yeoh GC, et al. Tumor necrosis factor-like weak inducer of apoptosis is a mitogen for liver progenitor cells. Hepatology (2010) 52(1):291-302. doi:10.1002/hep.23663.
81. Chen HN, Wang DJ, Ren MY, Wang QL, Sui SJ. TWEAK/Fn14 promotes the proliferation and collagen synthesis of rat cardiac fibroblasts via the NF-small ka, Cyrillic B pathway. Mol Biol Rep (2012) 39(8):8231-41. doi:10.1007/s11033-012-1671-3.
82. Banas B, Wornle M, Berger T, Nelson PJ, Cohen CD, Kretzler M, et al. Roles of SLC/CCL21 and CCR7 in human kidney for mesangial proliferation, migration, apoptosis, and tissue homeostasis. J Immunol (2002) 168(9):4301-7.
83. Sanz AB, Sanchez-Nino MD, Izquierdo MC, Jakubowski A, Justo P, Blanco-Colio LM, et al. TWEAK activates the non-canonical NFkappaB pathway in murine renal tubular cells: modulation of CCL21. PLoS One (2010) 5(1):e8955. doi:10.1371/journal.pone.0008955.
84. Maecker H, Varfolomeev E, Kischkel F, Lawrence D, Leblanc H, Lee W, et al. TWEAK attenuates the transition from innate to adaptive immunity. Cell (2005) 123(5):931-44. doi:10.1016/j.cell.2005.09.022.
85. Wang HY, Ma CA, Zhao Y, Fan X, Zhou Q, Edmonds P, et al. Antibody deficiency associated with an inherited autosomal dominant mutation in TWEAK. Proc Natl Acad Sci U S A (2013) 110(13):5127-32. doi:10.1073/pnas.1221211110.
86. Shainberg A, Yagil G, Yaffe D. Control of myogenesis in vitro by Ca2+ concentration in nutritional medium. Exp Cell Res (1969) 58(1):163-7. doi:10.1016/0014-4827(69)90127-X.
87. Yaffe D. Developmental changes preceding cell fusion during muscle differentiation in vitro. Exp Cell Res (1971) 66(1):33-48. doi:10.1016/S0014-4827(71)80008-3.
88. Cox PG, Gunter M. The effect of calcium ion concentration on myotube formation in vitro. Exp Cell Res (1973) 79(1):169-78. doi:10.1016/0014-4827(73)90502-8.
89. Schollmeyer JE. Role of Ca2+ and Ca2+-activated protease in myoblast fusion. Exp Cell Res (1986) 162(2):411-22. doi:10.1016/0014-4827(86)90346-0.
90. Paterson B, Strohman RC. Myosin synthesis in cultures of differentiating chicken embryo skeletal muscle. Dev Biol (1972) 29(2):113-38. doi:10.1016/0012-1606(72)90050-4.
91. Adamo S, Zani B, Siracusa G, Molinaro M. Expression of differentiative traits in the absence of cell fusion during myogenesis in culture. Cell Differ (1976) 5(1):53-67. doi:10.1016/0045-6039(76)90015-4.
92. Yaross MS, Konigsberg IR. Maintenance of proliferative capacity during avian myogenesis is independent of fusion-permissive calcium ion concentration. Exp Cell Res (1985) 158(2):360-70. doi:10.1016/0014-4827(85)90461-6.
93. Abbott KL, Friday BB, Thaloor D, Murphy TJ, Pavlath GK. Activation and cellular localization of the cyclosporine A-sensitive transcription factor NF-AT in skeletal muscle cells. Mol Biol Cell (1998) 9(10):2905-16. doi:10.1091/mbc.9.10.2905.
94. Michel RN, Chin ER, Chakkalakal JV, Eibl JK, Jasmin BJ. Ca2+/calmodulin-based signalling in the regulation of the muscle fibre phenotype and its therapeutic potential via modulation of utrophin A and myostatin expression. Appl Physiol Nutr Metab (2007) 32(5):921-9. doi:10.1139/H07-093.
95. Lee KH, Park JY, Kim K. NMDA receptor-mediated calcium influx plays an essential role in myoblast fusion. FEBS Lett (2004) 578(1-2):47-52. doi:10.1016/j.febslet.2004.10.076.
96. Knudsen KA, Horwitz AF. Toward a mechanism of myoblast fusion. Prog Clin Biol Res (1978) 23:563-8.
97. Nakanishi K, Dohmae N, Morishima N. Endoplasmic reticulum stress increases myofiber formation in vitro. FASEB J (2007) 21(11):2994-3003. doi:10.1096/fj.06-6408com.
98. Cowling BS, Mcgrath MJ, Nguyen MA, Cottle DL, Kee AJ, Brown S, et al. Identification of FHL1 as a regulator of skeletal muscle mass: implications for human myopathy. J Cell Biol (2008) 183(6):1033-48. doi:10.1083/jcb.200804077.
99. Horsley V, Jansen KM, Mills ST, Pavlath GK. IL-4 acts as a myoblast recruitment factor during mammalian muscle growth. Cell (2003) 113(4):483-94. doi:10.1016/S0092-8674(03)00319-2.
100. Serfling E, Berberich-Siebelt F, Avots A, Chuvpilo S, Klein-Hessling S, Jha MK, et al. NFAT and NF-kappaB factors-the distant relatives. Int J Biochem Cell Biol (2004) 36(7):1166-70. doi:10.1016/j.biocel.2003.07.002.
101. Cai T, Li X, Ding J, Luo W, Li J, Huang C. A cross-talk between NFAT and NF-kappaB pathways is crucial for nickel-induced COX-2 expression in Beas-2B cells. Curr Cancer Drug Targets (2011) 11(5):548-59. doi:10.2174/156800911795656001.
102. Liu Q, Chen Y, Auger-Messier M, Molkentin JD. Interaction between NFkappaB and NFAT coordinates cardiac hypertrophy and pathological remodeling. Circ Res (2012) 110(8):1077-86. doi:10.1161/CIRCRESAHA.111.260729.
103. Maruyama T, Fukushima H, Nakao K, Shin M, Yasuda H, Weih F, et al. Processing of the NF-kappa B2 precursor p100 to p52 is critical for RANKL-induced osteoclast differentiation. J Bone Miner Res (2010) 25(5):1058-67. doi:10.1359/jbmr.091032.
104. Yamaguchi N, Yokota M, Taguchi Y, Gohda J, Inoue J. cIAP1/2 negatively regulate RANKL-induced osteoclastogenesis through the inhibition of NFATc1 expression. Genes Cells (2012) 17(12):971-81. doi:10.1111/gtc.12012.
105. Abmayr SM, Pavlath GK. Myoblast fusion: lessons from flies and mice. Development (2012) 139(4):641-56. doi:10.1242/dev.068353.
106. Hindi SM, Tajrishi MM, Kumar A. Signaling mechanisms in mammalian myoblast fusion. Sci Signal (2013) 6(272):re2. doi:10.1126/scisignal.2003832.
107. Marino M, Scuderi F, Provenzano C, Bartoccioni E. Skeletal muscle cells: from local inflammatory response to active immunity. Gene Ther (2011) 18(2):109-16. doi:10.1038/gt.2010.124.
108. Milner DJ, Cameron JA. Muscle repair and regeneration: stem cells, scaffolds, and the contributions of skeletal muscle to amphibian limb regeneration. Curr Top Microbiol Immunol (2013) 367:133-59. doi:10.1007/82_2012_292.
109. Kataria NG, Bartold PM, Dharmapatni AA, Atkins GJ, Holding CA, Haynes DR. Expression of tumor necrosis factor-like weak inducer of apoptosis (TWEAK) and its receptor, fibroblast growth factor-inducible 14 protein (Fn14), in healthy tissues and in tissues affected by periodontitis. J Periodontal Res (2010) 45(4):564-73. doi:10.1111/j.1600-0765.2010.01275.x.
110. Dohi T, Burkly LC. The TWEAK/Fn14 pathway as an aggravating and perpetuating factor in inflammatory diseases: focus on inflammatory bowel diseases. J Leukoc Biol (2012) 92(2):265-79. doi:10.1189/jlb.0112042.
111. Hoffman EP, Brown RH Jr, Kunkel LM. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell (1987) 51(6):919-28. doi:10.1016/0092-8674(87)90579-4.
112. Wehling M, Spencer MJ, Tidball JG. A nitric oxide synthase transgene ameliorates muscular dystrophy in mdx mice. J Cell Biol (2001) 155(1):123-31. doi:10.1083/jcb.200105110.
113. Spencer MJ, Walsh CM, Dorshkind KA, Rodriguez EM, Tidball JG. Myonuclear apoptosis in dystrophic mdx muscle occurs by perforin-mediated cytotoxicity. J Clin Invest (1997) 99(11):2745-51. doi:10.1172/JCI119464.
114. Spencer MJ, Montecino-Rodriguez E, Dorshkind K, Tidball JG. Helper (CD4(+)) and cytotoxic (CD8(+)) T cells promote the pathology of dystrophin-deficient muscle. Clin Immunol (2001) 98(2):235-43. doi:10.1006/clim.2000.4966.
115. Farini A, Meregalli M, Belicchi M, Battistelli M, Parolini D, D'Antona G, et al. T and B lymphocyte depletion has a marked effect on the fibrosis of dystrophic skeletal muscles in the scid/mdx mouse. J Pathol (2007) 213(2):229-38. doi:10.1002/path.2213.
116. Arnold L, Henry A, Poron F, Baba-Amer Y, van Rooijen N, Plonquet A, et al. Inflammatory monocytes recruited after skeletal muscle injury switch into antiinflammatory macrophages to support myogenesis. J Exp Med (2007) 204(5):1057-69. doi:10.1084/jem.20070075.
117. Joe AW, Yi L, Natarajan A, Le Grand F, So L, Wang J, et al. Muscle injury activates resident fibro/adipogenic progenitors that facilitate myogenesis. Nat Cell Biol (2010) 12(2):153-63. doi:10.1038/ncb2015.
118. Lecourt S, Marolleau JP, Fromigue O, Vauchez K, Andriamanalijaona R, Ternaux B, et al. Characterization of distinct mesenchymal-like cell populations from human skeletal muscle in situ and in vitro. Exp Cell Res (2010) 316(15):2513-26. doi:10.1016/j.yexcr.2010.04.020.
119. Uezumi A, Fukada S, Yamamoto N, Takeda S, Tsuchida K. Mesenchymal progenitors distinct from satellite cells contribute to ectopic fat cell formation in skeletal muscle. Nat Cell Biol (2010) 12(2):143-52. doi:10.1038/ncb2014.
120. Uezumi A, Ito T, Morikawa D, Shimizu N, Yoneda T, Segawa M, et al. Fibrosis and adipogenesis originate from a common mesenchymal progenitor in skeletal muscle. J Cell Sci (2011) 124(Pt 21):3654-64. doi:10.1242/jcs.086629.
121. Schulz TJ, Huang TL, Tran TT, Zhang H, Townsend KL, Shadrach JL, et al. Identification of inducible brown adipocyte progenitors residing in skeletal muscle and white fat. Proc Natl Acad Sci U S A (2011) 108(1):143-8. doi:10.1073/pnas.1010929108.
122. Lee YH, Petkova AP, Mottillo EP, Granneman JG. In vivo identification of bipotential adipocyte progenitors recruited by beta3-adrenoceptor activation and high-fat feeding. Cell Metab (2012) 15(4):480-91. doi:10.1016/j.cmet.2012.03.009.
123. Heredia JE, Mukundan L, Chen FM, Mueller AA, Deo RC, Locksley RM, et al. Type 2 innate signals stimulate fibro/adipogenic progenitors to facilitate muscle regeneration. Cell (2013) 153(2):376-88. doi:10.1016/j.cell.2013.02.053.
124. Alexaki VI, Notas G, Pelekanou V, Kampa M, Valkanou M, Theodoropoulos P, et al. Adipocytes as immune cells: differential expression of TWEAK, BAFF, and APRIL and their receptors (Fn14, BAFF-R, TACI, and BCMA) at different stages of normal and pathological adipose tissue development. J Immunol (2009) 183(9):5948-56. doi:10.4049/jimmunol.0901186.
125. Chacon MR, Richart C, Gomez JM, Megia A, Vilarrasa N, Fernandez-Real JM, et al. Expression of TWEAK and its receptor Fn14 in human subcutaneous adipose tissue. Relationship with other inflammatory cytokines in obesity. Cytokine (2006) 33(3):129-37. doi:10.1016/j.cyto.2005.12.005.
126. Tiller G, Fischer-Posovszky P, Laumen H, Finck A, Skurk T, Keuper M, et al. Effects of TWEAK (TNF superfamily member 12) on differentiation, metabolism, and secretory function of human primary preadipocytes and adipocytes. Endocrinology (2009) 150(12):5373-83. doi:10.1210/en.2009-0488.
127. Kawashima R, Kawamura YI, Oshio T, Son A, Yamazaki M, Hagiwara T, et al. Interleukin-13 damages intestinal mucosa via TWEAK and Fn14 in mice-a pathway associated with ulcerative colitis. Gastroenterology (2011) 141(6):2119.e-29.e. doi:10.1053/j.gastro.2011.08.040.
128. Son A, Oshio T, Kawamura YI, Hagiwara T, Yamazaki M, Inagaki-Ohara K, et al. TWEAK/Fn14 pathway promotes a T helper 2-type chronic colitis with fibrosis in mice. Mucosal Immunol (2013) 6(6):1131-42. doi:10.1038/mi.2013.10.
129. Villalta SA, Rinaldi C, Deng B, Liu G, Fedor B, Tidball JG. Interleukin-10 reduces the pathology of mdx muscular dystrophy by deactivating M1 macrophages and modulating macrophage phenotype. Hum Mol Genet (2011) 20(4):790-805. doi:10.1093/hmg/ddq523.
130. Mounier R, Theret M, Arnold L, Cuvellier S, Bultot L, Goransson O, et al. AMPKalpha1 regulates macrophage skewing at the time of resolution of inflammation during skeletal muscle regeneration. Cell Metab (2013) 18(2):251-64. doi:10.1016/j.cmet.2013.06.017.
131. Deng B, Wehling-Henricks M, Villalta SA, Wang Y, Tidball JG. IL-10 triggers changes in macrophage phenotype that promote muscle growth and regeneration. J Immunol (2012) 189(7):3669-80. doi:10.4049/jimmunol.1103180.
132. Enwere EK, Boudreault L, Holbrook J, Timusk K, Earl N, Lacasse E, et al. Loss of cIAP1 attenuates soleus muscle pathology and improves diaphragm function in mdx mice. Hum Mol Genet (2013) 22(5):867-78. doi:10.1093/hmg/dds493.
133. Defronzo RA, Jacot E, Jequier E, Maeder E, Wahren J, Felber JP. The effect of insulin on the disposal of intravenous glucose. Results from indirect calorimetry and hepatic and femoral venous catheterization. Diabetes (1981) 30(12):1000-7. doi:10.2337/diab.30.12.1000.
134. Thiebaud D, Jacot E, Defronzo RA, Maeder E, Jequier E, Felber JP. The effect of graded doses of insulin on total glucose uptake, glucose oxidation, and glucose storage in man. Diabetes (1982) 31(11):957-63. doi:10.2337/diacare.31.11.957.
135. Shulman GI, Rothman DL, Jue T, Stein P, Defronzo RA, Shulman RG. Quantitation of muscle glycogen synthesis in normal subjects and subjects with non-insulin-dependent diabetes by 13C nuclear magnetic resonance spectroscopy. N Engl J Med (1990) 322(4):223-8. doi:10.1056/NEJM199001253220403.
136. Defronzo RA, Tripathy D. Skeletal muscle insulin resistance is the primary defect in type 2 diabetes. Diabetes Care (2009) 32(Suppl 2):S157-63. doi:10.2337/dc09-S302.
137. Rodeheffer MS. Tipping the scale: muscle versus fat. Nat Cell Biol (2010) 12(2):102-4. doi:10.1038/ncb0210-102.
138. Aguiari P, Leo S, Zavan B, Vindigni V, Rimessi A, Bianchi K, et al. High glucose induces adipogenic differentiation of muscle-derived stem cells. Proc Natl Acad Sci U S A (2008) 105(4):1226-31. doi:10.1073/pnas.0711402105.
139. Vazquez-Carballo A, Ceperuelo-Mallafre V, Chacon MR, Maymo-Masip E, Lorenzo M, Porras A, et al. TWEAK prevents TNF-alpha-induced insulin resistance through PP2A activation in human adipocytes. Am J Physio Endocrinol Metab (2013) 305(1):E101-12. doi:10.1152/ajpendo.00589.2012.
140. Diaz-Lopez A, Chacon MR, Bullo M, Maymo-Masip E, Martinez-Gonzalez MA, Estruch R, et al. Serum sTWEAK concentrations and risk of developing type 2 diabetes in a high cardiovascular risk population: a Nested Case-Control Study. J Clin Endocrinol Metab (2013) 98(8):3482-90. doi:10.1210/jc.2013-1848.
141. Maymo-Masip E, Fernandez-Veledo S, Garcia Espana A, Vazquez-Carballo A, Tinahones FJ, Garcia-Fuentes E, et al. The rise of soluble TWEAK levels in severely obese subjects after bariatric surgery may affect adipocyte-cytokine production induced by TNFalpha. J Clin Endocrinol Metab (2013) 98(8):E1323-33. doi:10.1210/jc.2012-4177.
142. Liu W, Liu Y, Lai X, Kuang S. Intramuscular adipose is derived from a non-Pax3 lineage and required for efficient regeneration of skeletal muscles. Dev Biol (2012) 361(1):27-38. doi:10.1016/j.ydbio.2011.10.011.
143. Mozzetta C, Consalvi S, Saccone V, Tierney M, Diamantini A, Mitchell KJ, et al. Fibroadipogenic progenitors mediate the ability of HDAC inhibitors to promote regeneration in dystrophic muscles of young, but not old Mdx mice. EMBO Mol Med (2013) 5(4):626-39. doi:10.1002/emmm.201202096.
144. Razani B, Reichardt AD, Cheng G. Non-canonical NF-kappaB signaling activation and regulation: principles and perspectives. Immunol Rev (2011) 244(1):44-54. doi:10.1111/j.1600-065X.2011.01059.x.